688046 药康生物
已收盘 08-20 15:00:00
资讯
新帖
简况
药康生物（688046）披露2026年半年度报告，8月19日股价下跌10.0%
证券之星 · 08-19 22:04
药康生物（688046）披露2026年半年度报告，8月19日股价下跌10.0%
药康生物(688046.SH)发布半年度业绩，归母净利润1.11亿元，同比增长56.28%
智通财经网 · 08-19 19:37
药康生物(688046.SH)发布半年度业绩，归母净利润1.11亿元，同比增长56.28%
药康生物(688046)6月30日股东户数0.78万户，较上期减少14.53%
证券之星 · 08-19 18:02
药康生物(688046)6月30日股东户数0.78万户，较上期减少14.53%
8月19日药康生物跌10.00%，诺安先锋混合A基金重仓该股
证券之星 · 08-19 16:40
8月19日药康生物跌10.00%，诺安先锋混合A基金重仓该股
每周股票复盘：药康生物（688046）因股价涨幅偏离值累计达30%登龙虎榜
证券之星 · 08-16
每周股票复盘：药康生物（688046）因股价涨幅偏离值累计达30%登龙虎榜
8月13日药康生物涨6.09%，诺安先锋混合A基金重仓该股
证券之星 · 08-13
8月13日药康生物涨6.09%，诺安先锋混合A基金重仓该股
8月10日药康生物涨12.25%，诺安先锋混合A基金重仓该股
证券之星 · 08-10
8月10日药康生物涨12.25%，诺安先锋混合A基金重仓该股
异动快报：药康生物（688046）8月10日9点37分触及涨停板
证券之星 · 08-10
异动快报：药康生物（688046）8月10日9点37分触及涨停板
8月7日药康生物涨19.99%，诺安先锋混合A基金重仓该股
证券之星 · 08-07
8月7日药康生物涨19.99%，诺安先锋混合A基金重仓该股
异动快报：药康生物（688046）8月7日10点11分触及涨停板
证券之星 · 08-07
异动快报：药康生物（688046）8月7日10点11分触及涨停板
每周股票复盘：药康生物（688046）新增18.62万股归属上市
证券之星 · 08-02
每周股票复盘：药康生物（688046）新增18.62万股归属上市
股市必读：药康生物（688046）新发布《2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市的公告》
证券之星 · 07-31
股市必读：药康生物（688046）新发布《2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市的公告》
7月30日药康生物跌8.35%，诺安先锋混合A基金重仓该股
证券之星 · 07-30
7月30日药康生物跌8.35%，诺安先锋混合A基金重仓该股
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市公告，7月29日股价下跌1.21%
证券之星 · 07-29
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市公告，7月29日股价下跌1.21%
7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股
证券之星 · 07-28
7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股
每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%
证券之星 · 07-26
每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%
信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参
每日经济新闻 · 07-23
信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参
药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务
美股速递 · 07-22
药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务
7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股
证券之星 · 07-22
7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股
股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元
证券之星 · 07-22
股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元
公司概况
公司名称：
江苏集萃药康生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-04-25
主营业务：
江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、模型创制、定制繁育、代理进出口及其他。
发行价格：
22.53
{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":36.7,"timestamp":1787209200000,"preClose":36,"halted":0,"volume":30625123,"delay":0,"changeRate":0.0194,"floatShares":409999999,"shares":409999999,"eps":0.4451,"marketStatus":"已收盘","change":0.7,"latestTime":"08-20 15:00:00","open":37.55,"high":38.8,"low":35.28,"amount":1130000000,"amplitude":0.0978,"askPrice":36.72,"askSize":1,"bidPrice":36.7,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.4451,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":36,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":39.6,"lowLimit":32.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410186200,"isCdr":false,"pbRate":6.64,"roa":"--","peRate":82.453381,"roe":"4.85%","epsLYR":0.35,"committee":0.785714,"marketValue":15054000000,"turnoverRate":0.0747,"status":0,"afterMarket":{"amount":594870.3,"volume":16209,"close":36.7,"buyVolume":4000,"sellVolume":0,"time":1787211237746,"indexStatus":"已收盘 08-20 15:30:00","preClose":36},"floatMarketCap":15054000000},"requestUrl":"/m/hq/s/688046/wiki","defaultTab":"wiki","newsList":[{"id":"2660429586","title":"药康生物（688046）披露2026年半年度报告，8月19日股价下跌10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429586?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:04","pubTimestamp":1787148262,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，药康生物报收于36.0元，较前一交易日下跌10.0%，最新总市值为147.67亿元。该股当日开盘39.6元，最高41.09元，最低35.27元，成交额达8.97亿元，换手率为5.85%。近日，江苏集萃药康生物科技股份有限公司披露2026年半年度报告。报告显示，公司2026年上半年实现营业收入459,550,008.70元，同比增长22.61%；归属于上市公司股东的净利润为110,814,393.33元，同比增长56.28%；扣除非经常性损益后的净利润为95,917,570.62元，同比增长52.43%。利润总额为124,269,473.18元，同比增长60.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900042863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660409364","title":"药康生物(688046.SH)发布半年度业绩，归母净利润1.11亿元，同比增长56.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660409364","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660409364?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:37","pubTimestamp":1787139469,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物 披露2026年半年度报告，报告期公司实现营业收入4.6亿元，同比增长22.61%;归属于上市公司股东的净利润1.11亿元，同比增长56.28%;扣非净利润9591.76万元，同比增长52.43%;基本每股收益0.27元;公司拟每10股派发现金红利1.3元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441716","title":"药康生物(688046)6月30日股东户数0.78万户，较上期减少14.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441716?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133742,"startTime":"0","endTime":"0","summary":"证券之星消息，近日药康生物披露，截至2026年6月30日公司股东户数为7812.0户，较3月31日减少1328.0户，减幅为14.53%。在医疗服务行业个股中，药康生物股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.82万户。从股价来看，2026年3月31日至2026年6月30日，药康生物区间涨幅为68.97%，在此期间股东户数减少1328.0户，减幅为14.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660445244","title":"8月19日药康生物跌10.00%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660445244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660445244?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:40","pubTimestamp":1787128832,"startTime":"0","endTime":"0","summary":"证券之星消息，8月19日药康生物跌10.00%，收盘报36.0元，换手率5.85%，成交量24.0万手，成交额8.97亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为46.02亿元，最新净值4.0447，较上一交易日下跌0.84%，近一年上涨31.82%。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900028310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659751731","title":"每周股票复盘：药康生物（688046）因股价涨幅偏离值累计达30%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2659751731","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659751731?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:50","pubTimestamp":1786816222,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，药康生物报收于40.5元，较上周的33.31元上涨21.59%。本周，药康生物8月13日盘中最高价报43.47元，股价触及近一年最高点。药康生物当前最新总市值166.13亿元，在医疗服务板块市值排名12/51，在两市A股市值排名1176/5207。本周关注点交易信息汇总：药康生物因连续3个交易日收盘价涨幅偏离值累计达30%登上龙虎榜。公司公告汇总：药康生物股票连续两日涨幅偏离值累计超30%，构成交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659327331","title":"8月13日药康生物涨6.09%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659327331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659327331?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:36","pubTimestamp":1786610169,"startTime":"0","endTime":"0","summary":"证券之星消息，8月13日药康生物涨6.09%创60日新高，收盘报40.95元，换手率7.92%，成交量32.47万手，成交额13.08亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为46.02亿元，最新净值3.9643，较上一交易日上涨0.41%，近一年上涨33.77%。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300026836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658989204","title":"8月10日药康生物涨12.25%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658989204?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:37","pubTimestamp":1786351038,"startTime":"0","endTime":"0","summary":"证券之星消息，8月10日药康生物涨12.25%创60日新高，收盘报37.39元，换手率8.62%，成交量35.38万手，成交额13.53亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000020553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099466","title":"异动快报：药康生物（688046）8月10日9点37分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658099466?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:45","pubTimestamp":1786326351,"startTime":"0","endTime":"0","summary":"证券之星8月10日盘中消息，9点37分药康生物（688046）触及涨停板。其所属行业医疗服务目前上涨。领涨股为药康生物。该股为基因编辑概念热股，当日基因编辑概念上涨3.03%。8月7日的资金流向数据方面，主力资金净流入6991.65万元，占总成交额13.98%，游资资金净流出3850.2万元，占总成交额7.7%，散户资金净流出3141.45万元，占总成交额6.28%。近5日资金流向一览见下表：药康生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000003937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616303","title":"8月7日药康生物涨19.99%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616303?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:39","pubTimestamp":1786091946,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日药康生物涨19.99%创60日新高，收盘报33.31元，换手率3.87%，成交量15.87万手，成交额5.0亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为46.02亿元，最新净值3.7894，较上一交易日上涨0.13%，近一年上涨28.91%。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369888","title":"异动快报：药康生物（688046）8月7日10点11分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657369888?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:15","pubTimestamp":1786068931,"startTime":"0","endTime":"0","summary":"证券之星8月7日盘中消息，10点11分药康生物（688046）触及涨停板。其所属行业医疗服务目前上涨。领涨股为药康生物。该股为基因编辑概念热股，当日基因编辑概念上涨2.61%。8月6日的资金流向数据方面，主力资金净流入510.88万元，占总成交额1.93%，游资资金净流出482.32万元，占总成交额1.82%，散户资金净流出28.56万元，占总成交额0.11%。近5日资金流向一览见下表：药康生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700012176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656988316","title":"每周股票复盘：药康生物（688046）新增18.62万股归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2656988316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656988316?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:57","pubTimestamp":1785607033,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，药康生物报收于24.15元，较上周的26.2元下跌7.82%。本周关注点公司公告汇总：药康生物完成限制性股票激励计划第三期归属，新增股份186,200股将于8月4日上市。公司公告汇总江苏集萃药康生物科技股份有限公司完成2022年限制性股票激励计划首次授予部分第三个归属期的股份登记，本次归属新增股份186,200股，已于2026年7月28日在中国证券登记结算有限责任公司上海分公司完成登记，上市流通日期为2026年8月4日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655802412","title":"股市必读：药康生物（688046）新发布《2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655802412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655802412?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:16","pubTimestamp":1785431811,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，药康生物报收于23.26元，下跌8.35%，换手率2.49%，成交量10.21万手，成交额2.44亿元。当日关注点交易信息汇总：7月30日主力资金净流出1200.18万元，占总成交额4.93%。公司公告汇总：药康生物完成2022年限制性股票激励计划首次授予部分第三个归属期登记，新增股份186,200股，股本由410,000,000股增至410,186,200股，上市流通日期为2026年8月4日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655482451","title":"7月30日药康生物跌8.35%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655482451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655482451?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:37","pubTimestamp":1785400649,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日药康生物跌8.35%，收盘报23.26元，换手率2.49%，成交量10.21万手，成交额2.44亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000025878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655289992","title":"药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期归属结果暨股份上市公告，7月29日股价下跌1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655289992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655289992?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:24","pubTimestamp":1785335063,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，药康生物报收于25.38元，较前一交易日下跌1.21%，最新总市值为104.06亿元。该股当日开盘25.72元，最高26.7元，最低24.64元，成交额达2.57亿元，换手率为2.46%。公告显示，公司完成2022年限制性股票激励计划首次授予部分第三个归属期的股份登记，本次归属新增股份186,200股，已于2026年7月28日在中国证券登记结算有限责任公司上海分公司完成登记，上市流通日期为2026年8月4日。股本总数由410,000,000股增至410,186,200股，未导致控股股东及实际控制人变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654907220","title":"7月28日药康生物跌6.10%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654907220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654907220?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:38","pubTimestamp":1785227923,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日药康生物跌6.10%，收盘报25.69元，换手率2.34%，成交量9.6万手，成交额2.52亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654503850","title":"每周股票复盘：药康生物（688046）上半年净利预增46.67%至60.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654503850","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654503850?lang=zh_cn&edition=full","pubTime":"2026-07-26 03:20","pubTimestamp":1785007223,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，药康生物报收于26.2元，较上周的23.2元上涨12.93%。本周，药康生物7月22日盘中最高价报28.85元。本周关注点来自业绩披露要点：药康生物预计2026年上半年归母净利润同比增长46.67%至60.78%。公司公告汇总江苏集萃药康生物科技股份有限公司预计2026年半年度实现归属于母公司所有者的净利润10,400万元至11,400万元，同比增长46.67%至60.78%；扣除非经常性损益后的净利润为9,200万元至10,000万元，同比增长46.20%至58.92%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600001126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791754","title":"信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791754","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653791754?lang=zh_cn&edition=full","pubTime":"2026-07-23 07:02","pubTimestamp":1784761351,"startTime":"0","endTime":"0","summary":"｜2026年7月23日星期四｜NO.1信达生物：全球首款口服周制剂小分子GLP-1申报临床7月21日，信达生物IBI3042的临床试验申请获国家药监局受理。今年6月，公司已在美国糖尿病学会（ADA）年会上披露了包括IBI3042在内的多项代谢管线数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233817817194.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233817817194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688046","01801","159938","JDOC","09939","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143060040","title":"药康生物与GCCL签署合作备忘录，共推全球药物发现与开发服务","url":"https://stock-news.laohu8.com/highlight/detail?id=1143060040","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143060040?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729653,"startTime":"0","endTime":"0","summary":"药康生物与GCCL公司签署了一份谅解备忘录，旨在共同推进全球药物发现与开发服务。这一战略合作标志着双方在整合资源与专业技术方面迈出了关键一步，致力于为全球生物医药研发提供更高效、更创新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753623","title":"7月22日药康生物涨10.66%，诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653753623?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:42","pubTimestamp":1784709759,"startTime":"0","endTime":"0","summary":"证券之星消息，7月22日药康生物涨10.66%，收盘报27.0元，换手率5.47%，成交量22.44万手，成交额6.11亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共25家，其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653041162","title":"股市必读：药康生物（688046）预计2026年1-6月扣非后净利润盈利9200万元至1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653041162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653041162?lang=zh_cn&edition=full","pubTime":"2026-07-22 01:03","pubTimestamp":1784653394,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，药康生物报收于24.4元，上涨8.35%，换手率4.6%，成交量18.87万手，成交额4.25亿元。业绩披露要点业绩预告预计2026年1-6月扣非后净利润盈利9200万元至1亿元；归属净利润盈利1.04亿元至1.14亿元。公司公告汇总药康生物2026年半年度业绩预告的自愿性披露公告预计2026年半年度实现归属于母公司所有者的净利润10,400万元至11,400万元，同比增长46.67%至60.78%；扣除非经常性损益后的净利润为9,200万元至10,000万元，同比增长46.20%至58.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200001326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787251929644,"stockEarnings":[{"period":"1week","weight":-0.1038},{"period":"1month","weight":0.5041},{"period":"3month","weight":0.7753},{"period":"6month","weight":1.18},{"period":"1year","weight":1.0683},{"period":"ytd","weight":1.4156}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7812人(较上一季度减少14.53%)","perCapita":"52507股","listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","registeredCapital":"41018万元","survey":" 江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、模型创制、定制繁育、代理进出口及其他。","listedPrice":22.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}